Tango Therapeutics, Inc. - 8-K Filing
Tango Therapeutics announced that Daniella Beckman will no longer serve as Chief Financial Officer, effective April 15, 2026. The company entered into a Separation Agreement with Beckman on May 7, 2026, providing her with twelve months of severance pay at her current base salary and reimbursement for up to twelve months of COBRA premiums. Additionally, the agreement accelerates vesting of equity awards as if she had continued employment for an additional twenty-four months. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 9.01 Financial Statements and Exhibits)
Tickers: $TNGX